Zevra Therapeutics is trading at $10.75, up 5.10% from the October 14 regular-session close of $10.23, with no confirmed news trigger.
- No fresh company announcement explaining the rise was identified; its latest listed release was September 2.
- Major U.S. indexes fell during the session, so broad-market weakness does not explain the after-hours gain.
- Available evidence does not establish a specific catalyst; the move may reflect trading activity.